Last reviewed · How we verify
TRC105 and Bevacizumab
At a glance
| Generic name | TRC105 and Bevacizumab |
|---|---|
| Also known as | Chimeric Antibody (TRC105) to CD105, Avastin |
| Sponsor | Tracon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer (PHASE1)
- Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
- Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC (PHASE1)
- Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) (PHASE2)
- A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma (PHASE2)
- TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma (PHASE2)
- Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated (PHASE1)
- Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |